SMTI at a glance
Sanara MedTech Inc. (SMTI, SEC CIK 714256) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on October 1, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Sanara MedTech Inc. (SMTI) reported revenue of $103.1 million (up 19.0% from FY2024) and a net loss of $37.6 million. Diluted EPS was -$4.36.
- As of June 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Sanara MedTech Inc. (SMTI) shares worth $22.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $103.1M
- +19.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 18 funds
- $22.5M · +2 vs prior quarter
- Latest 8-K
- Oct 1, 2026
- Item 8.01 · Item 5.07
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- THP discontinued in September 2025; single Sanara Surgical reportable segment thereafter
- BIASURGE Vizient contract effective January 1, 2026, expanding contracted hospital access
- Merger expected by year-end with $33.00 cash plus 0.4735 Parent shares per Sanara share
- Near-term headwinds: merger approvals, competition, product acceptance, supply disruptions, and capital requirements
Risk Factors
- Newly added transaction risk: MiMedx merger announced July 29, 2026, subject to uncompleted closing conditions
- Most material update: $9,660,336 termination fee if specified merger-termination conditions occur
- Regulatory and legal risk: Lawsuits could obtain injunctions preventing or delaying merger completion
- Operational risk: Merger uncertainty may increase employee attrition and hinder qualified-personnel recruitment
- Financial risk: Failed merger would leave Sanara bearing substantial advisory, legal, accounting, and related expenses
AI summary of the SMTI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- MiMedx refiled its HSR notification September 15, restarting regulatory review of the proposed merger
- HSR waiting period scheduled to expire October 15, 2026, unless extended or terminated earlier
Item 5.07: Submission of Matters to a Vote of Security Holders
- Merger with MiMedx approved, clearing the key shareholder vote for Sanara to become MiMedx’s wholly owned subsidiary
- Proposal No. 1 passed overwhelmingly: 6,372,989 for, 1,944 against, and 36,494 abstentions
Item 2.02: Results of Operations and Financial Condition
- Filing contains only signature information dated August 11, 2026
- No earnings figures or operating results included in the provided Item 2.02 text
Item EX-99.1: Item EX-99.1
- Q2 revenue rose 9% to $28.1M, led by soft-tissue products up 11%; bone-fusion sales declined 8%
- Gross margin improved to 93% from 92%, but operating income fell to $1.8M as expenses increased 14% to $24.4M
Item 7.01: Regulation FD Disclosure
- Proposed MiMedx–Sanara business combination remains subject to regulatory approvals and Sanara stockholder approval
- Transaction timing and anticipated benefits remain uncertain, with potential abandonment if closing conditions fail
Item 1.01: Entry into a Material Definitive Agreement
- MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per SMTI share, with stock component valued at $2.00
- Board-unanimous transaction creates a MiMedx subsidiary, subject to majority stockholder approval and regulatory clearances
AI summaries of SMTI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SMTI
Don't miss the next SMTI filing
- Alerts as it files. A push when SMTI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SMTI, by share count.
- Ask anything. An AI agent that reads every SMTI filing and answers with sources.
SMTI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Yon Seth D | F | Sep 15, 2026 | 3,661 | $35.11 |
| TANZBERGER ERIC D | A | Jun 4, 2026 | 5,308 | - |
| Salamone Ann Beal | A | Jun 4, 2026 | 4,154 | - |
| Myers Keith G | A | Jun 4, 2026 | 4,385 | - |
| DeSutter Robert Andrew | A | Jun 4, 2026 | 5,539 | - |
| Nixon Ronald T | A | Jun 4, 2026 | 4,154 | - |
| Mack Roszell III | A | Jun 4, 2026 | 5,308 | - |
| Ortwein Sara N | A | Jun 4, 2026 | 4,616 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $86.7M | $103.1M |
| Gross Profit | - | $78.5M | $95.6M |
| Operating Income | - | -$6.7M | $7.3M |
| Net Income | - | -$9.7M | -$37.6M |
| Gross Margin | - | 90.6% | 92.7% |
| Op. Margin | - | -7.7% | 7.1% |
| Net Margin | - | -11.2% | -36.4% |
| Balance Sheet | |||
| Total Assets | $73.9M | $88.1M | $72.9M |
| Equity | - | $39.4M | $5.9M |
| ROE | - | -24.5% | -632.5% |
| Per Share | |||
| EPS | - | $-1.14 | $-4.36 |
| Cash Flow | |||
| Operating CF | - | -$24K | $6.8M |
| CapEx | $265K | $206K | $4.6M |
Source: XBRL data in Sanara MedTech Inc. (SMTI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SMTI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 18 | $22.5M |
| Q1 2026 | 16 | $12.1M |
| Q4 2025 | 15 | $14.5M |
| Q3 2025 | 17 | $21.4M |
| Q2 2025 | 17 | $19.0M |
| Q1 2025 | 13 | $13.3M |
| Q4 2024 | 11 | $14.0M |
| Q3 2024 | 7 | $4.6M |
- AQR Capital Management+72.3K (+181%)
- Goldman Sachs Group+52.6K (+244%)
- Vanguard Capital Management LLC+43.5K (+29%)
- BlackRock+20.1K (+9%)
- T. Rowe Price Group+8.4K (+77%)
- JPMorgan Chase & Co−3.7K (-58%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 114 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SMTI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | May 18, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
| 8-K | Mar 24, 2026 | - | - | - |
| 10-K | Mar 24, 2026 | Dec 31, 2025 | - | |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 23, 2026 | - | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
SMTI SEC filings: frequently asked questions
Which institutions hold SMTI stock?
As of June 30, 2026, the largest Sanara MedTech Inc. (SMTI) holders among the 13F filers tracked by SignalX were BlackRock ($5.9 million), Vanguard Capital Management LLC ($4.6 million), AQR Capital Management ($2.6 million), Goldman Sachs Group ($1.8 million), Renaissance Technologies LLC ($1.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SMTI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Sanara MedTech Inc. (SMTI) reported revenue of $103.1 million (up 19.0% from FY2024) and a net loss of $37.6 million. Diluted EPS was -$4.36. The figures come from the XBRL data in the 10-K.
What did SMTI report in its latest 8-K?
Sanara MedTech Inc. (SMTI) filed an 8-K on October 1, 2026 reporting Item 8.01 (Other Events) and Item 5.07 (Submission of Matters to a Vote of Security Holders). MiMedx refiled its HSR notification September 15, restarting regulatory review of the proposed merger.
What are the latest SMTI SEC filings?
Sanara MedTech Inc. (SMTI) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on October 1, 2026 and a Form 4 insider filing on September 16, 2026.
What is SMTI's SEC CIK number?
Sanara MedTech Inc. (SMTI)'s SEC Central Index Key (CIK) is 714256. EDGAR lists every SMTI filing under that number.
Ask anything about SMTI
The research agent reads SMTI's filings, financials, insider trades and 13F holders, then answers with sources.